Table 3.
CMR Imaging Findings COVID-19–Positive Athletes
| Overall (N = 48) | Symptomatic COVID-19 (n = 37 [77]) | Asymptomatic COVID-19 (n = 11 [23]) | p Value | |
|---|---|---|---|---|
| Left heart | ||||
| LVEF, % | 59.91 (56.64–62.88) | 60.32 (56.66–63.33) | 59.09 (54.79–61.64) | 0.32 |
| LVEF <50 % | 1 (2) | 1 (3) | 0 (0) | |
| LVEDV index, ml/m2 | 105.29 (94.15–117.73) | 104.74 (93.09–117.17) | 114.44 (99.52–118.69) | 0.11 |
| LVESV index, ml/m2 | 41.7 (37.49–47.72) | 39.81 (37.17–45.38) | 46.82 (41.18–50.44) | 0.02∗ |
| Right heart | ||||
| RVEF% | 53.58 (48.33–59.43) | 54.60 (47.55–59.77) | 51.32 (50.82–57.22) | 0.74 |
| RVEDV index, ml/m2 | 95.21 (86.69–106.93) | 92.40 (82.91–107.33) | 99.82 (95.46–105.28) | 0.08 |
| RVESV index, ml/m2 | 44.12 (37.57–50.68) | 43.2 (36.76–51.27) | 46.80 (43.44–48.16) | 0.19 |
| Native T1, ms | 969.0 (950.0–984.0) | 973.0 (950.0–984.75) | 963.0 (951.3–974.0) | 0.54 |
| Abnormal native T1 ≥990 ms | 9 (19) | 8 (22) | 1 (9) | 0.66 |
| Upper tercile native T1 | 15 (31) | 13 (35) | 2 (18) | 0.46 |
| Native T2, ms | 44.00 (42.00–45.00) | 44.00 (42.00–45.00) | 44.00 (42.00–44.75) | 0.53 |
| Abnormal native T2, >52 ms | 0 (0) | 0 (0) | 0 (0) | |
| Upper tercile native T2 | 6 (13) | 6 (16) | 0 (0) | 0.31 |
| LGE | 1 (2) | 1 (3) | 0 (0) | |
| Pericardial enhancement | 19 (40) | 10 (27) | 9 (82) | 0.003∗ |
| Small pericardial effusion ≥5 mm | 28 (58) | 20 (54) | 8 (73) | 0.31 |
Values are median (interquartile range) or n (%).
LGE = late gadolinium enhancement; RVEDV = right ventricular end-diastolic volume; RVEF = right ventricular ejection fraction; RVESV = right ventricular end-systolic volume; other abbreviations as in Table 2.
∗
p < 0.05 between the symptomatic and asymptomatic COVID-19 group. The p values were calculated using Mann-Whitney U test where median is reported and the Fisher exact test where frequencies are reported.